Carbylan Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of combination therapies. The Company’s focus is on the development of Hydros-TA, its intra-articular injectable product candidate to treat pain associated with osteoarthritis (OA) of the knee. The Hydros-TA is a cross-linked combination of low dose corticosteroid and hyaluronic acid viscosupplement, designed to provide OA pain relief through a single intra-articular injection. Its technology includes drug/device combination products under development based on chemically engineered polymer systems incorporating hyaluronic acid, a polysaccharide present in the human body. Hydros-TA utilizes crosslinking technology to deliver both short-term pain relief with a low dose corticosteroid triamcinolone acetonide (TA) and sustained pain relief from its hyaluronic acid viscosupplement. The Company has not generated any revenues.
